Statistics

Total Visits

Views
Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)60

Select a period of time:

Number of views in the range

Views
Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)36

Views

Views
January 20252
February 20257
March 202514
April 202513
May 20250
June 20250
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore14
Hong Kong10
United States9
Germany2
Spain1
 

Top cities views

Views
Hong Kong10
Council Bluffs1